<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218162</url>
  </required_header>
  <id_info>
    <org_study_id>ID-LAS-301</org_study_id>
    <nct_id>NCT04218162</nct_id>
  </id_info>
  <brief_title>Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Parallel Group Study to Evaluate Efficacy and Safety of Lasmiditan Compared to Placebo in the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled parallel group study to evaluate efficacy and
      safety of lasmiditan tablet compared to Placebo in the acute treatment of Migraine
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Headache Pain Free at 2 Hours Post Dose</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants defined as mild, moderate, or severe headache pain becoming none.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Headache Relief</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Headache Recurrence</measure>
    <time_frame>2 Hours Post Dose Up to 48 Hours</time_frame>
    <description>The number of participants with headache recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Use of Rescue Medication</measure>
    <time_frame>From 2 Hours Post Dose Up to 24 Hours</time_frame>
    <description>The percentage of participants who used rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>From Baseline Up to End of Study</time_frame>
    <description>Safety and tolerability was assessed by the number of participants with at least 1 treatment adverse emergent event.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Acute Migraine</condition>
  <arm_group>
    <arm_group_label>Lasmiditan 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan 50mg</intervention_name>
    <description>Lasmiditan 50mg</description>
    <arm_group_label>Lasmiditan 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan 100mg</intervention_name>
    <description>Lasmiditan 100mg</description>
    <arm_group_label>Lasmiditan 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able and willing to give written informed consent.

          -  Male or female, aged 18 years or above.

          -  Participants with migraine with or without aura fulfilling the International Headache
             Society (IHS) diagnostic criteria 1.1 and 1.2.1 (International Headache Classification
             (ICHD-3).

          -  History of disabling migraine for at least 1 year.

          -  Migraine Disability Association (MIDAS) score ≥11.

          -  Migraine onset before the age of 50 years.

          -  History of 3 - 8 migraine attacks per month (&lt; 15 headache days per month).

          -  Females of child-bearing potential must be using or willing to use a highly effective
             form of contraception (e.g. combined oral contraceptive, intrauterine device (IUD),
             abstinence or vasectomized partner).

          -  Able and willing to complete an electronic diary to record details of the migraine
             attack treated with study drug.

        Exclusion Criteria:

          -  Any medical condition or clinical laboratory test which in the judgment of the
             Investigator makes the participant unsuitable for the study.

          -  Pregnant or breast-feeding women.

          -  Known hypersensitivity to lasmiditan or to any excipient of lasmiditan oral tablets,
             or any sensitivity to lasmiditan.

          -  History or evidence of hemorrhagic stroke, epilepsy or any other condition placing the
             participant at increased risk of seizures.

          -  History of recurrent dizziness and/or vertigo including benign paroxysmal positional
             vertigo (BPPV), Meniere's disease, vestibular migraine, and other vestibular
             disorders.

          -  History of diabetes mellitus with complications (diabetic retinopathy, nephropathy or
             neuropathy).

          -  History within the previous three years or current evidence of abuse of any drug,
             prescription or illicit, or alcohol.

          -  History of orthostatic hypotension with syncope.

          -  Significant renal or hepatic impairment.

          -  Participant is at imminent risk of suicide (positive response to question 4 or 5) on
             the Columbia-Suicide Severity Rating Scale (C-SSRS) or had a suicide attempt within
             six months prior to screening.

          -  Participation in any clinical trial of an experimental drug or device in the previous
             30 days.

          -  Known Hepatitis B or C or human immunodeficiency virus(HIV) infection. History, within
             past 12 months, of chronic migraine or other forms of primary or secondary chronic
             headache disorder (e.g. hemicranias continua, medication overuse headache) where
             headache frequency is ≥15 headache days per month.

          -  Use of more than 3 doses per month of either opiates or barbiturates.

          -  Initiation of or a change in concomitant medication to reduce the frequency of
             migraine episodes within three (3) months prior to Screening/Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

